Abattis Bioceuticals Corp.
ATTBF · OTC
9/30/2019 | 6/30/2019 | 3/31/2019 | 12/31/2018 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.12 | -0.02 | 0.39 | 0.07 |
| FCF Yield | -9.62% | 41.33% | -3.07% | -4.33% |
| EV / EBITDA | -25.97 | -22.02 | -15.62 | -19.29 |
| Quality | ||||
| ROIC | -3.20% | -4.75% | -8.21% | -13.01% |
| Gross Margin | 71.66% | 59.77% | 100.00% | 100.00% |
| Cash Conversion Ratio | -4.25 | -10.19 | 4.14 | 1.14 |
| Growth | ||||
| Revenue 3-Year CAGR | 709,214.95% | – | – | – |
| Free Cash Flow Growth | -114.69% | 1,334.09% | 57.71% | 3.92% |
| Safety | ||||
| Net Debt / EBITDA | 1.06 | 1.56 | 3.56 | 1.67 |
| Interest Coverage | -10.97 | -246.85 | 0.00 | -682.48 |
| Efficiency | ||||
| Inventory Turnover | 0.24 | 0.18 | 0.00 | 0.00 |
| Cash Conversion Cycle | 129.02 | 142.25 | 1,679.66 | 78,387.76 |